Alpha Tau Medical Ltd ( (DRTS) ) has released its Q1 earnings. Here is a breakdown of the information Alpha Tau Medical Ltd presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, is focused on the research, development, and potential commercialization of its innovative alpha-radiation cancer therapy, Alpha DaRT, for the treatment of solid tumors.
In the first quarter of 2025, Alpha Tau Medical Ltd. reported significant progress in its clinical trials and financial performance. The company shared promising interim results from trials using Alpha DaRT in treating pancreatic cancer and head and neck squamous cell carcinoma, and announced FDA approvals for new U.S. pilot studies.
Key highlights include a 75% systemic objective response rate in a combination trial with Keytruda, FDA approvals for pilot studies in pancreatic cancer and glioblastoma, and a $36.9 million financing to support ongoing activities. The company’s R&D expenses increased to $7.2 million, reflecting its intensified research efforts, while it reported a net loss of $8.7 million for the quarter.
Looking ahead, Alpha Tau is poised to continue its momentum with upcoming clinical trials and facility expansions. The company remains focused on advancing its Alpha DaRT technology through regulatory pathways and expanding its market presence, supported by its strengthened financial position and strategic partnerships.